FR2804685B1 - Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine - Google Patents

Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine

Info

Publication number
FR2804685B1
FR2804685B1 FR0001527A FR0001527A FR2804685B1 FR 2804685 B1 FR2804685 B1 FR 2804685B1 FR 0001527 A FR0001527 A FR 0001527A FR 0001527 A FR0001527 A FR 0001527A FR 2804685 B1 FR2804685 B1 FR 2804685B1
Authority
FR
France
Prior art keywords
leptospire
diagnosis
animal
protein
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0001527A
Other languages
English (en)
Other versions
FR2804685A1 (fr
Inventor
Fontaine Genevieve Andre
Christine Branger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole Nationale Veterinaire de Toulouse ENVT
Original Assignee
Ecole Nationale Veterinaire de Toulouse ENVT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Nationale Veterinaire de Toulouse ENVT filed Critical Ecole Nationale Veterinaire de Toulouse ENVT
Priority to FR0001527A priority Critical patent/FR2804685B1/fr
Priority to AU2001235636A priority patent/AU2001235636A1/en
Priority to US10/203,253 priority patent/US20030124567A1/en
Priority to PCT/FR2001/000373 priority patent/WO2001059123A1/fr
Priority to EP01907739A priority patent/EP1254233A1/fr
Publication of FR2804685A1 publication Critical patent/FR2804685A1/fr
Application granted granted Critical
Publication of FR2804685B1 publication Critical patent/FR2804685B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0001527A 2000-02-08 2000-02-08 Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine Expired - Fee Related FR2804685B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0001527A FR2804685B1 (fr) 2000-02-08 2000-02-08 Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine
AU2001235636A AU2001235636A1 (en) 2000-02-08 2001-02-08 Use of a leptospire protein for preventing and/or diagnosing and/or treating animal and/or human leptospirosis
US10/203,253 US20030124567A1 (en) 2000-02-08 2001-02-08 Use of a leptospire protein preventing and/or diagnosing and/or treating animal or human leptospirosis
PCT/FR2001/000373 WO2001059123A1 (fr) 2000-02-08 2001-02-08 Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine
EP01907739A EP1254233A1 (fr) 2000-02-08 2001-02-08 Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001527A FR2804685B1 (fr) 2000-02-08 2000-02-08 Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine

Publications (2)

Publication Number Publication Date
FR2804685A1 FR2804685A1 (fr) 2001-08-10
FR2804685B1 true FR2804685B1 (fr) 2004-08-13

Family

ID=8846749

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0001527A Expired - Fee Related FR2804685B1 (fr) 2000-02-08 2000-02-08 Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine

Country Status (5)

Country Link
US (1) US20030124567A1 (fr)
EP (1) EP1254233A1 (fr)
AU (1) AU2001235636A1 (fr)
FR (1) FR2804685B1 (fr)
WO (1) WO2001059123A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447278B1 (fr) * 2002-10-10 2015-04-08 Cornell Research Foundation, Inc. Nouvelles protéines immunogènes de Leptospira
FR2846658B1 (fr) * 2002-10-30 2007-03-30 Virbac Peptides pour la prevention, le diagnostic et le traitement de la leptospirose animale et/ou humaine.
GB201015223D0 (en) * 2010-09-13 2010-10-27 Sec Dep For Environment Food A Vaccines
CN120271701B (zh) * 2025-06-11 2025-10-03 吉林大学 抗致病性钩端螺旋体的单链抗体、制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306623B1 (en) * 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32

Also Published As

Publication number Publication date
EP1254233A1 (fr) 2002-11-06
AU2001235636A1 (en) 2001-08-20
WO2001059123A1 (fr) 2001-08-16
FR2804685A1 (fr) 2001-08-10
US20030124567A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
DE69731309D1 (de) Impfstofformel auf polynukleotidbasis zur behandlung von hundekrankheiten, insbesondere solcher des atmungs- und verdauungstraktes
DE69528604D1 (de) Medikamentenbehandlung erkrankter tiefliegender bereiche im inneren des körpers
DE69942614D1 (de) Vorrichtung zur diagnose und therapie von elektrophysiologischen krankheiten
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
EP1187844A4 (fr) Polymorphisme de carbamyl phosphate synthetase 1 humaine ; methodes diagnostiques et therapeutiques y relatifs
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
DZ3360A1 (fr) Infusion des liquides à l'intèrieur du corps humain ou animal
EP1173191A4 (fr) Nouveaux agents peptidiques anti-angiogeniques, utilisation de ces derniers pour la therapie et le diagnostic
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
TNSN99133A1 (fr) Procede perfectionne pour la preparation de bases de schiff et produits ainsi obtenus
EP1409000A4 (fr) Utilisation de (agaricus blazei) murill pour la prevention ou le traitement de maladies de la peau ou autres
FR2776657B1 (fr) Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
EP0888381A4 (fr) Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation
FR2804685B1 (fr) Utilisation d'une proteine de leptospire pour la prevention et/ou le diagnostic et/ou le traitement de la leptospirose animale et/ou humaine
EP1532162A4 (fr) Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
EP1575993A4 (fr) Methodes de traitement de patients et d'identification de therapeutique
DE59704432D1 (de) Vorrichtung zur endoskopischen Diagnose und Behandlung von Gewebe
EP1546714A4 (fr) Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain
FR2846658B1 (fr) Peptides pour la prevention, le diagnostic et le traitement de la leptospirose animale et/ou humaine.
FR2730633B1 (fr) Cabine pour la remise en forme ou le traitement hygienique corporel d'un individu
EP1322778A4 (fr) Utilisation de cyr61 dans le traitement et le diagnostic des leiomyomes uterins chez la femme
EP1669085A4 (fr) Agent therapeutique pour la prevention et/ou le traitement de la maladie d'alzheimer
EP1420776A4 (fr) Medicaments destines au traitement de lesion cerebrale et methodes d'utilisation correspondantes

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20181031